GlassScriptPhysician profile
Maqsood Javed
NPI 1073568713
$4,345.23
in general payments reported to CMS, 2019-2025
36 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $834 · 2021: $14.43 · 2022: $695 · 2023: $598 · 2024: $549 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.68 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $933.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $589.12 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $461.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $361.59 | 2019-2020 | |
| Amgen INC. | $246.35 | 2019-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $180.12 | 2019-2023 | Myrbetriq |
| Lilly USA, LLC | $169.15 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $155.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.75 | 2019-2025 | Ofev |
| Pfizer INC. | $126.82 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.25 | 2022-2024 | |
| Exact Sciences Corporation | $73.63 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $64.50 | 2020-2024 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $62.39 | 2021-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.72 | 2019-2025 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $50.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $47.27 | 2019-2020 | |
| Mylan Specialty L.P. | $45.79 | 2020-2022 | |
| Philips North America LLC | $35.67 | 2020 | |
| Boston Scientific Corporation | $34.63 | 2022 | |
| Abbvie INC. | $33.61 | 2022-2023 | |
| Allergan, INC. | $30.87 | 2020 | |
| Abiomed | $29.21 | 2025 | |
| Corcept Therapeutics | $24.39 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $23.71 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $22.65 | 2022 | |
| Shield Therapeutics INC | $21.69 | 2023 | Accrufer |
| Lundbeck LLC | $20.42 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $19.83 | 2023 | Krystexxa |
| Averitas Pharma INC. | $18.80 | 2023 | Qutenza |
| Antares Pharma, INC. | $15.63 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.76 | 2019 | |
| Melinta Therapeutics, LLC | $14.51 | 2019 | |
| Merck Sharp & Dohme LLC | $12.64 | 2020 | |
| Genentech USA, INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maqsood Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.